LONGBIO-B(01779.HK) closed 37.21% higher, the Hang Seng Pharmaceuticals & Biotechnology Sector saw divergent trends

NewTimeSpace News: LONGBIO-B(01779.HK)  was officially listed on the Main Board of HKEX on June 5, 2026. The stock closed its debut session at HK$131.8, climbing HK$35.74 or 37.21% compared with the IPO offer price of HK$96.06. It registered an intraday high of HK$158 and an intraday low of HK$126.4, with total trading turnover of HK$619 million and latest market capitalisation at HK$9.612 billion.

On the sector front, the Hang Seng Pharmaceuticals & Biotechnology Sector, to which LONGBIO-B belongs, showed an overall divergence trend, with 64 stocks advancing and 80 stocks declining.Among the gainers, LONGBIO-B closed higher by 37.21%, FRONTAGE closed higher by 19.57%, ESSEX BIO-TECH closed higher by 5.17%, TENNOR THERAP-B closed higher by 4.66%, GOLDEN THROAT closed higher by 4.48%.Among the decliners, LUZHU BIOTECH-B closed lower by 12.97%, IMPACT THERAP-B closed lower by 7.63%, TRANSTHERA-B closed lower by 7.06%, HAIXI PHARMA closed lower by 6.75%, RECBIO-B closed lower by 6.61%.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.